Ewha Med J.  1993 Dec;16(4):373-382. 10.12771/emj.1993.16.4.373.

Effect of Conjugated Equine Estrogens on Plasma Lipoprotein in Postmenopausal Women

• Yu HK

• KMID: 1965091
• DOI: http://doi.org/10.12771/emj.1993.16.4.373

Abstract

The postmenopausal state is characterized by an absence of ovulation and a reduction of ovarian estrogen secretion. Postmenopausal women is associated with several symptoms including vasomotor flushes, atrophic vaginitis, osteoporosis and increased risk of cardiovascular disease. Varying doses of estrogenic preparation have been used to treat these symptoms and have displayed changes in plasma lipoprotein level. We administered different doses of oral conjugated estrogen to 30 postmenopusal women and made comparative analysis of lipoprotein changes by varying doses. The results were as follows : 1) The changes of plasma estradiol after estrogen replacement therapy in group I and group II were increased by 54.96+/-11.36 pg/ml(p<0.01) and 68.37+/-16.91 pg/ml(p<0.01), but the difference of changes between two group was not statistically significant(p>0.05). 2) The changes of plasma FSH after estrogen replacement therapy in group I and group II were decreased by 52.94+/-12.95 MIU/ml(p<0.O5), and 60.24+/-8.09 MIU/ml(p<0.01), and difference of changes between two groups was not statistically significant(P>0.05). 3) The changes of plasma cholesterol after estrogen replacement therapy in group I and group II were decreased 17.I+/-4.28 mg/dl(p<0.01) and 11.07+/-9.01 mg/dl(p>0.05), and differenee of changes between two groups was not statistically significant(p>0.05). 4) The changes of plasma triglyceride after estrogen replacement therapy in group I andgroup II were decresead by 145.3+/-20.3 mg/dl(p>0.05) and 35.4+/-13.87 mg/dl(p>0.O5), but difference of changes between two groups was not statistically significant(p>0.05). 5) The changes of plasma HDL after estrogen replacement therapy in group I and group II were increased by 3.0+/-3.50 mg/dl(p>0.05) and 11.05+/-5.30 mg/dl(p<0.05). 6) The change of plasma HDL/cholesterol after estrogen replacement therapy in group I and group II were increased by 5.9+/-1.33% (p<0.01) and 6.31+/-2.19% (p<0.05), but difference of changes between two groups was statistically significant(p>0.05). 7) The changes of plasma LDL/cholesterol after estrogen replacement therapy in group I and group II were decreased by 3.01+/-2.7% (p<0.01) and 7.71+/-2.13% (p<0.01), but difference of changes between two groups was not statistically significant(p>0.05). 8) The changes of plasma VLD/cholesterol after estrogen replacement therapy in group I and group II were increased by 1.81+/-2.54% (p>0.05) and 5.30+/-2.38% (p>0.O5) and difference of changes between two groups was statistically significant(p>0.O5). 9) The changes of plasma HDL/LDL after estrogen replacement therapy in group I andgroup II were increased by 0.21+/-0.04% (p<0.01) and 0.247+/-0.06(p<0.01), but difference of changes between two groups was statistically significant(p>0.05).

MeSH Terms

Atrophic Vaginitis
Cardiovascular Diseases
Cholesterol
Estradiol
Estrogen Replacement Therapy
Estrogens
Estrogens, Conjugated (USP)*
Female
Humans
Lipoproteins*
Osteoporosis
Ovulation
Plasma*
Triglycerides
Cholesterol
Estradiol
Estrogens
Estrogens, Conjugated (USP)
Lipoproteins